首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 再生医学细胞疗法基因疗法

欧洲细胞和基因治疗製造服务市场预测至 2030 年 - 区域分析 - 按类型、适应症（癌症、骨科等）、应用（临床製造和商业製造）和最终用户

市场调查报告书

商品编码

1452624

欧洲细胞和基因治疗製造服务市场预测至 2030 年 - 区域分析 - 按类型、适应症（癌症、骨科等）、应用（临床製造和商业製造）和最终用户

Europe Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 119 Pages | 订单完成后即时交付

价格

简介目录图表

欧洲细胞和基因治疗製造服务市场预计将从2022年的18.7977亿美元成长到2030年的65.6385亿美元。预计2022年至2030年CAGR为16.9%。

公司的策略性倡议推动欧洲细胞和基因治疗製造服务市场

在细胞和基因治疗製造服务市场中运营的公司专注于策略发展，例如合作、扩张、协议、伙伴关係和新产品发布，这有助于他们提高销售、扩大地理覆盖范围并增强迎合市场需求的能力。比现有的客户群更大。以下提到了细胞和基因治疗製造服务市场的一些值得注意的发展。

2023 年 5 月，Lonza 推出了 TheraPEAK T-VIVO 细胞培养基，采用新型化学成分确定的配方，旨在优化和简化 CAR T 细胞的製造。与其他无血清培养基不同，TheraPEAK T-VIVO 细胞培养基无需添加人类血清或其成分即可表现出高性能。

2022年10月，辉瑞公司完成了对Biohaven Pharmaceutical Holding Company Ltd.的收购，Biohaven Pharmaceutical Holding Company Ltd.是NURTEC ODT（rimegepant）的製造商，NURTEC ODT（rimegepant）是一种创新的偏头痛疗法，被核准用于成人发作性偏头痛的急性治疗和预防。

2022 年 3 月，Cellevolve Bio 与西雅图儿童治疗公司合作，开发和商业化用于儿童癌症的新型多重 CAR。根据此次合作，合作伙伴将专注于 BrainChild 研究项目，该项目由五种多重 CAR 组成，用于治疗儿童中枢神经系统 (CNS) 恶性肿瘤。透过合作，他们将利用西雅图儿童治疗工厂设施对新 CAR 进行早期临床 GMP 研究。

因此，这些策略措施为细胞和基因治疗製造服务市场创造了巨大的成长机会。

欧洲细胞与基因治疗製造服务市场概述

欧洲细胞和基因治疗製造服务市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。该地区将在未来几年占据重要的市场份额。由于产能建设投资、政府的大力支持和对该地区的参与等因素，欧洲、美国和欧洲的细胞和基因治疗製造服务市场预计将在预测期内显着增长。此外，顶级竞争者的出现将进一步促进 2022-2030 年预测期内区域市场的成长。

德国拥有强大的製药业，尤其註重研发。该国拥有 660 家生技公司，僱用 5 万名员工。其中，660家公司专注于CGT。根据 NecstGen 的报告，2021 年正在进行超过 29 项评估 CAR 修饰免疫细胞的活跃临床试验，其中大部分生产涉及 CAR-T 细胞。此外，德国迄今已进行了超过50项基因治疗临床研究。德国 CGT 公司的创新努力主要集中在地方或国家层面，因为它们缺乏国际影响力。

英国是世界上先进疗法的研究、开发、製造、临床采用和报销的最佳生态系统之一。目前，英国正在进行超过 85 项临床试验，70 家 CGT 公司正在开发潜在的治疗方法。 2018年，英国国家医疗服务体系（NHS）宣布为癌症患者提供CAR-T细胞治疗，这是首次为这些患者提供这种疗法。

Catapult 是另一家为英国 CGT 生态系统做出重大贡献的顶级公司；它是该国开发製造工艺的前五名公司之一。该公司正在开发更智慧的自动化 CGT 製造流程，能够以最少的干预自动适应不断变化的环境和流程要求。因此，这些公司在提高生产力和降低最终成本方面所做的努力是推动英国欧洲细胞和基因治疗製造服务市场成长的主要因素。此外，由于对研究的持续和有针对性的投资，英国在欧洲细胞和基因治疗製造服务市场中占据强势地位。

欧洲细胞和基因治疗製造服务市场收入及 2030 年预测（百万美元）

欧洲细胞和基因治疗製造服务市场细分

欧洲细胞和基因治疗製造服务市场分为类型、适应症、应用、最终用户和国家。

根据类型，欧洲细胞和基因治疗製造服务市场分为细胞治疗和基因治疗。 2022年，细胞治疗领域在欧洲细胞和基因治疗製造服务市场中占据更大份额。细胞治疗部分进一步分为自体细胞治疗和同种异体细胞治疗。基因治疗部分进一步细分为病毒载体和非病毒载体。

根据迹象，欧洲细胞和基因治疗製造服务市场分为癌症、骨科等。 2022年，癌症领域在欧洲细胞和基因治疗製造服务市场中占据最大份额。

根据应用，欧洲细胞和基因治疗製造服务市场分为临床製造和商业製造。 2022年，商业製造领域在欧洲细胞和基因治疗製造服务市场中占据最大份额。

根据最终用户，欧洲细胞和基因治疗製造服务市场分为製药和生物技术公司和合约研究组织（CRO）。 2022年，製药和生物技术公司部门在欧洲细胞和基因治疗製造服务市场中占据更大份额。

根据国家/地区，欧洲细胞和基因治疗製造服务市场分为英国、法国、德国、西班牙、义大利和欧洲其他地区。 2022年，英国在欧洲细胞和基因治疗製造服务市场中占据最大份额。

Catalent Inc、Charles River Laboratories International Inc、FUJIFILM Holdings Corp、Lonza Group AG、Merck KgaA、Nikon Corp、Oxford BioMedica Plc、Takara Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是该领域的一些领先公司。欧洲细胞细胞细胞和基因治疗製造服务市场。

Companies operating in the cell and gene therapy manufacturing services market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the cell and gene therapy manufacturing services market are mentioned below.

In May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation devised to optimize and streamline CAR T-cell manufacturing. The TheraPEAK T-VIVO Cell Culture Medium can exhibit a high performance without the need to add human serum or its components, unlike other serum-free media.

In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.

In March 2022, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for paediatric cancers. Under the collaboration, the partners will focus on the BrainChild research program, a suite of five multiplex CARs, to treat pediatric central nervous system (CNS) malignancies. In partnership, they would leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs.

Thus, these strategic initiatives create significant growth opportunities in the cell and gene therapy manufacturing services market.

Europe Cell and Gene Therapy Manufacturing Services Market Overview

The Europe cell and gene therapy manufacturing services market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region will hold a significant market share in the coming years. The European US and Europe cell and gene therapy manufacturing services market is expected to witness significant growth during the forecast period due to factors such as the investment for setup of production capacity, high government support and involvement in the region. Also, presence of top competitive players will further enhance the regional market growth during the forecast period 2022-2030.

Germany has a strong pharmaceutical industry with a notable focus on R&D. The country has 660 biotechnology companies that employ 50,000 employees. Among these, 660 companies are focused on CGT. As per the NecstGen report, more than 29 active clinical trials evaluating CAR-modified immune cells were ongoing in 2021, and the majority of the production involved CAR-T cells. Also, over 50 clinical studies have been conducted in gene therapy in Germany so far. The innovation efforts of German CGT companies are majorly focused on the local or country level, as they lack international presence.

The UK is one of the world's best ecosystems for research, development, manufacturing, clinical adoption, and reimbursement of advanced therapeutics. Currently, over 85 clinical trials are ongoing in the UK, and 70 CGTs companies are operating for the development of potentially curative therapies. In 2018, National Health Services (NHS) England announced the availability of CAR-T cell treatment for cancer patients, which was the first time when this therapy was made available to these patients.

Catapult is another top company that has been contributing significantly to the CGT ecosystem in the UK; it stands as one of the top five companies in developing manufacturing processes in the country. The company is developing smarter automated CGT manufacturing processes that can automatically adapt to changing environments and process requirements with minimal intervention. Therefore, efforts made by these companies for enhancing productivity and reducing the final costs are the major factors driving the growth of the Europe cell and gene therapy manufacturing services market in the UK. Moreover, the UK holds a strong position in the Europe cell and gene therapy manufacturing services market in Europe owing to sustained and targeted investment in research.

Europe Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)

Europe Cell and Gene Therapy Manufacturing Services Market Segmentation

The Europe cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.

Based on type, the Europe cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Europe cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Europe cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Europe cell and gene therapy manufacturing services market.

Based on application, the Europe cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Europe cell and gene therapy manufacturing services market.

Based on end user, the Europe cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Europe cell and gene therapy manufacturing services market.

Based on country, the Europe cell and gene therapy manufacturing services market is segmented into the UK, France, Germany, Spain, Italy, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe cell and gene therapy manufacturing services market.

Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Oxford BioMedica Plc, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the Europe cell and gene therapy manufacturing services market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Cell and Gene Therapy Manufacturing Services Market Landscape

4.1 Overview
4.2 Europe PEST Analysis

5. Europe Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics

5.1 Key Market Drivers:
- 5.1.1 Increase in Number of Approval of Cell and Gene Therapies
- 5.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
5.2 Market Restraints
- 5.2.1 High Cost of Cell and Gene Therapy Manufacturing
5.3 Market Opportunities
- 5.3.1 Strategic Initiatives by Companies
5.4 Future Trends
- 5.4.1 Automation of Cell and Gene Therapy Manufacturing Services
5.5 Impact Analysis:

6. Europe Cell and Gene Therapy Manufacturing Services Market - Europe Market Analysis

6.1 Europe Cell and Gene Therapy Market Revenue (US$ Mn), 2022 - 2030

7. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

7.1 Overview
7.2 Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cell Therapy
- 7.3.1 Overview
- 7.3.2 Cell Therapy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.3.2.1 Autologous
    - 7.3.2.1.1 Overview
    - 7.3.2.1.2 Autologous: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.3.2.2 Allogenic
    - 7.3.2.2.1 Overview
    - 7.3.2.2.2 Allogenic: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Gene Therapy
- 7.4.1 Overview
- 7.4.2 Gene Therapy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.4.2.1 Viral Vector
    - 7.4.2.1.1 Overview
    - 7.4.2.1.2 Viral Vector: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.4.2.2 Non-Viral Vector
    - 7.4.2.2.1 Overview
    - 7.4.2.2.2 Non-Viral Vector: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

8.1 Overview
8.2 Europe Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
8.3 Cancer
- 8.3.1 Overview
- 8.3.2 Cancer: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Orthopedics
- 8.4.1 Overview
- 8.4.2 Orthopedics: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

9.1 Overview
9.2 Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
9.4 Clinical Manufacturing
- 9.4.1 Overview
- 9.4.2 Clinical Manufacturing: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Commercial Manufacturing
- 9.5.1 Overview
- 9.5.2 Commercial Manufacturing: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

10.1 Overview
10.2 Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
10.4 Pharmaceutical and Biotechnology Companies
- 10.4.1 Overview
- 10.4.2 Pharmaceutical & Biotechnology Companies: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
10.5 Contract Research Organizations (CROs)
- 10.5.1 Overview
- 10.5.2 Contract Research Organizations (CROs): Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country Analysis

11.1 Overview
- 11.1.1 Europe: Europe Cell and Gene Therapy Manufacturing Services Market, By Country, 2022 & 2030 (%)
  - 11.1.1.1 Germany: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.1.1 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.1.1.1 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.1.1.2 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.1.2 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.1.3 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.1.4 Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.2 UK: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.2.1 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.2.1.1 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.2.1.2 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.2.2 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.2.3 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.2.4 UK: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.3 France: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.3.1 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.3.1.1 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.3.1.2 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.3.2 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.3.3 France: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.3.4 France: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.4 Italy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.4.1 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.4.1.1 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.4.1.2 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.4.2 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.4.3 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.4.4 Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.5 Spain: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.5.1 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.5.1.1 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.5.1.2 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.5.2 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.5.3 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.5.4 Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
  - 11.1.1.6 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    - 11.1.1.6.1 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
    - 11.1.1.6.1.1 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
    - 11.1.1.6.1.2 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
    - 11.1.1.6.2 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
    - 11.1.1.6.3 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
    - 11.1.1.6.4 Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

12. Europe Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

12.1 Overview
12.2 Growth Strategies in Europe Cell and Gene Therapy Manufacturing Services Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Thermo Fisher Scientific Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Merck KGaA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Charles River Laboratories International Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Lonza Group AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 WuXi AppTec Co Ltd?
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Catalent Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Takara Bio Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Nikon Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 FUJIFILM Holdings Corp
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Oxford BioMedica Plc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

简介目录图表

List Of Tables

Table 1. Europe Cell and Gene Therapy Market Segmentation
Table 2. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 3. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 4. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 5. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 6. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 7. Germany: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 8. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 9. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 10. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 11. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 12. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 13. UK: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 14. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 15. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 16. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 17. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 18. France: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 19. France: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 20. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 21. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 22. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 23. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 24. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 25. Italy: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 26. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 27. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 28. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 29. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 30. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 31. Spain: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 32. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 33. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 34. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 35. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 36. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 37. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 38. Recent Organic Growth Strategies in Europe Cell and Gene Therapy Manufacturing Services Market
Table 39. Recent Inorganic Growth Strategies in the Europe Cell and Gene Therapy Manufacturing Services Market

List Of Figures

Figure 1. Europe Cell and Gene Therapy Market Segmentation, By Country
Figure 2. Europe PEST Analysis
Figure 3. Europe Cell and Gene Therapy Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Europe Cell and Gene Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 6. Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 7. Cell Therapy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Autologous: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Allogenic: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Gene Therapy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Viral Vector: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Non-Viral Vector: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Europe Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
Figure 14. Cancer: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Orthopedics: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Others: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 18. Clinical Manufacturing: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Commercial Manufacturing: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 21. Pharmaceutical & Biotechnology Companies: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Contract Research Organizations (CROs): Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Europe: Cell and Gene Therapy Manufacturing Services Market, by Key Region - Revenue (2022) (US$ Million)
Figure 24. Europe: Europe Cell and Gene Therapy Manufacturing Services Market, By Country, 2022 & 2030 (%)
Figure 25. Germany: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. UK: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. France: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Italy: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Spain: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Rest of Europe: Europe Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Growth Strategies in Europe Cell and Gene Therapy Manufacturing Services Market

02-2729-4219

+886-2-2729-4219

License/价格

欧洲细胞和基因治疗製造服务市场预测至 2030 年 - 区域分析 - 按类型、适应症（癌症、骨科等）、应用（临床製造和商业製造）和最终用户

Europe Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type, Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User

目录

第 1 章：简介

第 2 章：执行摘要

第 3 章：研究方法

第 4 章：欧洲细胞与基因疗法製造服务市场格局

第 5 章：欧洲细胞和基因治疗製造服务市场 - 主要产业动态

第 6 章：欧洲细胞与基因治疗製造服务市场 - 欧洲市场分析

第 7 章：欧洲细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 按类型

第 8 章：2030 年欧洲细胞和基因治疗製造服务市场分析和预测 - 按指标

第 9 章：欧洲细胞和基因治疗製造服务市场 - 收入和 2030 年预测 -按应用

第 10 章：欧洲细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 按最终用户

第 11 章：欧洲细胞和基因治疗製造服务市场 - 收入和 2030 年预测 - 国家分析

第 12 章：欧洲细胞与基因治疗製造服务市场 - 产业格局

第 13 章：公司简介

Table Of Contents